Your browser doesn't support javascript.
loading
Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.
Gordon, K B; Gottlieb, A B; Langely, R G; van de Kerkhof, P; Belasco, K T; Sundaram, M; Okun, M; Serra, L.
Affiliation
  • Gordon KB; Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
J Eur Acad Dermatol Venereol ; 29(4): 767-76, 2015 Apr.
Article in En | MEDLINE | ID: mdl-25284275
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Quality of Life / Anti-Inflammatory Agents, Non-Steroidal / Adalimumab Type of study: Prognostic_studies Aspects: Patient_preference Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Eur Acad Dermatol Venereol Journal subject: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Year: 2015 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Quality of Life / Anti-Inflammatory Agents, Non-Steroidal / Adalimumab Type of study: Prognostic_studies Aspects: Patient_preference Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Eur Acad Dermatol Venereol Journal subject: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Year: 2015 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido